Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 3, Issue 1, Pages 35-44Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.09.76
Keywords
immunosuppression; lymphoma; non-Hodgkin lymphoma; post-transplant lymphoproliferative disorder; solid-organ transplantation
Categories
Ask authors/readers for more resources
A post-transplant lymphoproliferative disorder (PTLD) is an uncommon but serious complication following solid-organ transplantation. The incidence varies, depending on the type of organ transplanted, the degree of immunosuppression, the number of episodes of acute rejection and a patient's immune status to Epstein Barr virus. The incidence of PTLD is thought to be bimodal; cases in the first year after solid-organ transplantation are typically related to Epstein Barr virus. A second incidence occurs more than 1 year following transplantation and is typically not related to Epstein Barr virus. A variety of therapeutic approaches has been used for these patients, with more recent strategies including the use of rituximab, with or without combination chemotherapy. Efforts continue to be made to improve the outcome of patients with PTLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available